Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
{{output}}
Purpose: The cyclin-dependent kinase (CDK), CDK12, is mutated or amplified in multiple cancers. We previously described a subtype of prostate cancer characterized predominantly by frameshift, loss-of-function mutations in CDK12. ... ...
